<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR12">
 <label>12.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Locatelli</surname>
    <given-names>F</given-names>
   </name>
   <name>
    <surname>Neville</surname>
    <given-names>KA</given-names>
   </name>
   <name>
    <surname>Rosolen</surname>
    <given-names>A</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Phase 1/2 study of brentuximab vedotin in pediatric patients with relapsed or refractory (R/R) Hodgkin Lymphoma (HL) or systemic Anaplastic Large-Cell Lymphoma (sALCL): preliminary phase 2 data for brentuximab vedotin 1.8 Mg/Kg in the HL study arm</article-title>
  <source>Blood. ASH annual meeting</source>
  <year>2013</year>
  <volume>122</volume>
  <fpage>4378</fpage>
 </element-citation>
</ref>
